SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is trending as the community debates its potential to break through previous highs and drop a zero amidst high social media activity. While some traders express skepticism regarding its longevity, others are actively encouraging aggressive accumulation and engagement to fuel a rally.

Dumb SEND IT

The $DSIT (Dumb SEND IT) community is aggressively pushing for a breakout, driven by the anticipation of official chart integration and a forthcoming website launch. Holders are actively engaged in community-led pump efforts and air-drop incentives, positioning the token as a resilient, community-driven play against skeptics and early profit-takers.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is currently in the spotlight following the announcement of a preliminary Phase 3 trial design for its lead candidate, CAD-1005, aimed at treating heparin-induced thrombocytopenia. While some community members are optimistic about the company's clinical pipeline and potential regulatory progress, others are expressing significant skepticism due to heavy bot-driven social media activity and concerns over the company's long-term capital needs.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending following media reports that GameStop is building a stake in the company as a potential acquisition target, sparking widespread debate among investors over the financial feasibility and strategic logic of a merger. Community discussions are highly polarized, with many skeptical of the deal's mechanics while others are closely tracking institutional data and potential share accumulation patterns.

Urban One, Inc. is a multi-media company, which engages in radio broadcasting that targets African-American and urban listeners. It operates through the following segments: Radio Broadcasting, Reach Media, Digital, and Cable Television. The Radio Broadcasting segment consists of all radio broadcast results of operations and low powered television operations. The Reach Media segment consists of the results of operations for the related activities and operations of the company’s syndicated shows. The Digital segment focuses on its online business, including the operations of Interactive One. The Cable Television segment deals with TV One and CLEO TV operations. The company was founded by Catherine L. Hughes in 1980 and is headquartered in Silver Spring, MD.

Urban One Inc - Ordinary Shares - Class A

Urban One Inc

Urban One is gaining traction as investors speculate on a potential rally leading up to Juneteenth, a trend that has historically drawn significant attention to the stock. The conversation is currently fueled by discussions around micro-float mechanics, recent acquisition news, and comparisons to previous parabolic moves.

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Sanofi - ADR

Sanofi-Aventis

Sanofi is currently attracting significant investor attention as market participants speculate on the company's M&A strategy, particularly regarding potential acquisitions in the obesity, MASH, and immunology sectors. Community discourse is heavily focused on Sanofi's recent pipeline developments and the perceived need for the pharmaceutical giant to expand its portfolio to counter long-term patent cliff challenges.

Cantor Equity Partners II, Inc. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was founded on November 11, 2020 and is headquartered in New York, NY.

Cantor Equity Partners II Inc. - Ordinary Shares - Class A

Cantor Equity Partners II Inc

Cantor Equity Partners II is gaining attention as it nears its business combination with Securitize, a leading tokenization infrastructure provider that counts BlackRock and Morgan Stanley among its backers. Community sentiment is highly bullish, with investors positioning themselves in what they view as a rare pure-play opportunity to gain exposure to the emerging real-world asset tokenization market.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following reports that the company is preparing a potential takeover bid for eBay, fueling community speculation on how a strategic merger could transform the retailer into a larger e-commerce powerhouse. The stock is currently dominated by intense retail participation and heightened options activity as traders debate the viability of a large-scale acquisition, potential dilution, and the broader implications for the company's long-term growth trajectory.

Pinterest, Inc. engages in the operation of a pinboard-style photo-sharing website. It allows users to create and manage theme-based image collections such as events, interests, and hobbies. The company was founded by Benjamin Silbermann, Paul Cahill Sciarra, and Evan Sharp in October 2008 and is headquartered in San Francisco, CA.

Pinterest Inc - Ordinary Shares - Class A

Pinterest Inc

Pinterest is experiencing significant volatility as investors react to a revenue miss and cautious forward guidance, while the community actively debates whether the stock is an oversold value opportunity or a long-term play in need of new leadership. Sentiment remains divided between those betting on a technical bounce supported by the company's strong cash position and those frustrated by management's inability to capitalize on a large, active user base.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

Seres Therapeutics is experiencing heightened investor attention driven by unusual volume and sustained price momentum, sparking renewed community discussions regarding potential buyout scenarios or strategic partnerships. Shareholders remain focused on whether this activity signals a significant corporate development ahead of upcoming fiscal windows, despite ongoing caution from some market participants wary of historical volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Vascular surgeons Dr. Patrick Geraghty and Dr. Patrick Muck — who led the earlier study — will head the new trial.</li><li>Separately, the company also announced that it has initiated a voluntary recall in the U.S. for its CGuard Prime 135 cm carotid stent delivery system.</li><li>The company also withdrew its full-year 2026 revenue guidance.</li></ul>&nbsp;Shares of InspireMD (NSPR) jumped 30% after hours on Friday after the company announced that the U.S. Food and Drug Administration has approved its application to start the CGUARDIANS III pivotal study of the SwitchGuard Neuro-Protection System, overshadowing the pessimism around the firm dropping its 2026 financial guidance.The trial will test the safety and effectiveness of SwitchGuard when used with the company’s CGuard Prime carotid stent during transcarotid artery revascularization or TCAR procedures. The device reverses blood flow to catch debris and help prevent strokes in patients with carotid artery disease.Vascular surgeons Dr. Patrick Geraghty and Dr. Patrick Muck — who led the earlier study — will head the new trial.“This is an important step toward offering a complete TCAR solution,” said CEO Marvin Slosman. The company hopes to launch SwitchGuard in the U.S. in 2027 if approved.InspireMD already won FDA approval for its CGuard Prime stent in June 2025.<h2 class="st-heading-2">Recall And Dropped Guidance</h2>Separately, the company also announced that it has initiated a voluntary recall in the U.S. for its CGuard Prime 135 cm carotid stent delivery system.The company said the delivery system did not meet technical performance expectations during a controlled commercial launch for carotid artery stenting (CAS) procedures. The recall applies only to the delivery system and does not affect the CGuard stent implant itself.There are no safety concerns for patients who have already received the implanted stent. InspireMD is pausing U.S. sales of the 135 cm version while it makes design improvements. The company expects FDA approval for the original CGuard delivery system in the third quarter of 2026 and for the enhanced Prime version in the first half of 2027. As a result, it has withdrawn its full-year 2026 revenue guidance.“Management believes this is the most prudent step given the impact of the temporary discontinuation of commercial activity in the U.S. pending the anticipated FDA approval of its original CGuard stent delivery system in the third quarter of 2026,” the company said.More details will be provided at the company’s first quarter earnings on May 4, InspireMD added.<h2 class="st-heading-2">How Did NSPR Retail Traders React?</h2>On Stocktwits, retail sentiment around NSPR stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘normal’ levels.A Stocktwits user expressed skepticism about upcoming dilution.<stembedurl>https://www.stocktwits.com/Thespectator/message/652062806</stembedurl>Another user dismissed the application news as nothing more than regular updates from biotech companies.<stembedurl>https://www.stocktwits.com/vcaelum/message/652062730</stembedurl><a href="https://stocktwits.com/symbol/NSPR">NSPR stock</a> has fallen 56% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-uone-stock-rally-38-percent-today/cZQVLLCReeY">Why Did UONE Stock Rally 38% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Shares of Beam Global rose premarket on Thursday. (Representative image: Getty Images)

NSPR Rallies After Hours On FDA Green Light for Key Stroke-Prevention Trial Despite Withdrawn Annual Guidance

The trial will test the safety and effectiveness of SwitchGuard when used with the company’s CGuard Prime carotid stent during transcarotid artery revascularization or TCAR procedures.

Equity

The trial will test the safety and effectiveness of SwitchGuard when used with the company’s CGuard Prime carotid stent during transcarotid artery revascularization or TCAR procedures.


<ul class="summary-bullets"><li>Achieve on Monday appointed physician Andrew D. Goldberg as CEO and a member of its Board of Directors.</li><li>Separately, the company also said that it has entered into a securities purchase agreement with leading healthcare investors for a private placement of its securities for gross proceeds up to approximately $354 million.&nbsp;</li><li>Achieve is now looking forward to launching cytisinicline for nicotine dependence in the first half of 2027.</li></ul> Shares of Achieve Life Sciences Inc. (ACHV) gained 42% on Thursday after the company appointed a new CEO, shortly after announcing a private placement of up to $354 million, as it gears towards getting regulatory approval for its experimental drug for the treatment of nicotine dependence.The stock is on track to clock its best day since February 2019, if gains hold.<h2 class="st-heading-2">New CEO, Board Appointments</h2>Achieve on Monday appointed physician Andrew D. Goldberg as CEO and a member of its Board of Directors. Goldberg, who most recently served as a Portfolio Manager at Marshall Wace, will replace Richard Stewart as CEO.The company also appointed Lucian Iancovici and Aaron E. Royston as members of the company’s board of directors.<h2 class="st-heading-2">Fresh Funding</h2>Separately, the company also said that it has entered into a securities purchase agreement with leading healthcare investors for a private placement of its securities.The placement includes an initial upfront funding of approximately $180 million and an additional amount of up to approximately $174 million on exercise of milestone-driven warrants. The net proceeds from the placement is expected to fund a clinical trial for cytisinicline for e-cigarette cessation, the commercialization of cytisinicline, and for working capital and general corporate purposes, the company said.<h2 class="st-heading-2">Near-Term Milestones</h2>Achieve is now looking forward to the U.S. Food and Drug Administration’s approval of cytisinicline as a treatment for nicotine dependence.Earlier this week, the company said that it expects the FDA to reject its current application by June 20, provided that the agency found manufacturing concerns at its third-party manufacturing facility. Once the formal rejection is received, the company expects to resubmit its application naming &nbsp;Adare Pharma Solutions as its manufacturer for commercial supply in the fourth quarter of 2026, it said. The company continues to expect to launch cytisinicline in the first half of 2027.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around ACHV stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.A Stocktwits user expressed optimism for the company getting acquired after approval for cytisinicline.<stembedurl>https://www.stocktwits.com/Biotech_Pharma_Investor/message/650482761</stembedurl>Another user expressed optimism for a good year following the “professional” announcements.<stembedurl>https://www.stocktwits.com/Sieppo/message/650471510</stembedurl><a href="https://stocktwits.com/symbol/ACHV">ACHV stock</a> has more than doubled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/hubc-stock-tanks-after-massive-rally-reverse-split/cZJvo99RIDA">HUBC Stock Declines 35% After A Whopping Two-Day Rally – What’s Driving The Change In Momentum?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Achieve Life Sciences logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally?

Though Achieve Life Sciences expects the FDA to reject its current cytisinicline application for the treatment of nicotine dependence, the company is hopeful of imminent approval following a resubmission in the fourth quarter. 

<ul class="summary-bullets"><li>The private placement, worth $4 million, is expected to close around April 7th.&nbsp;</li><li>Focus Universal said that the offering consisted of the sale of about 1.12 million common units, each comprising either a share or a pre-funded warrant, plus Series A and Series B warrants to buy shares at $3.33.&nbsp;</li><li>The company said that it expects to use the net proceeds from the offering for general corporate purposes and working capital.</li></ul>Shares of Nevada-based Focus Universal Inc. (FCUV) rallied more than 67% on Monday after the company announced a private placement worth $4 million.Focus Universal, which provides patented hardware and software design technologies, said that it had entered into definitive agreements with institutional investors for the private placement of its common stock and pre-funded and investor warrants at a price of $3.58 per share.The transaction is expected to close around April 7, the company said.<h2 class="st-heading-2">Private Placement Details</h2>Focus Universal said that the offering consisted of the sale of about 1.12 million common units, each comprising either a share or pre-funded warrant, plus Series A and Series B warrants to buy shares at $3.33.Each unit was priced at $3.58, or at about $3.579 for pre-funded units, equal to the offering price per common share minus an exercise price of $0.00001 per pre-funded warrant.The company said that the pre-funded warrants are immediately exercisable with no expiry. Series A warrants, with an initial exercise price of $3.33 per share would also be exercisable immediately and expire in 24 months, while Series B warrants will expire in 60 months. Each pre-funded unit replaces one common unit in the offering structure.Focus Universal said that it expects to use the net proceeds from the offering for general corporate purposes and working capital.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around FCUV shares jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours.Meanwhile, message volumes surged from ‘low’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/FCUV">FCUV stock</a> has lost about 36% so far this year.Meanwhile, <a href="https://stocktwits.com/symbol/IWC">iShares Micro-Cap ETF</a> (IWC), which tracks micro-capitalization U.S. companies, has risen about 3.25% in the same time.Also Read: <a href="https://stocktwits.com/news-articles/markets/equity/plug-stock-rises-most-in-a-month-retail-turns-bullish-on-hydrogen-deal/cZJ4HG3RIYm">PLUG Stock Rises Most In A Month — Retail Turns Bullish On Hydrogen Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is FCUV Stock Surging More Than 67% Today?

Nevada-based Focus Universal on Monday announced that it had entered into definitive agreements with institutional investors for the private placement of its common stock, and pre-funded and investor warrants. 

This Micro-Cap Tech Stock Surged More Than 67% Today — Here’s Why

<ul class="summary-bullets"><li>The company stated that it intends to use the proceeds of the stock offering to meet its working capital requirements as well as other general corporate needs.</li><li>Last week, Outlook Therapeutics announced a new $18.4 million non-convertible unsecured note financing, stating that it will use a portion of the net proceeds to pay down an existing note.</li><li>In December 2025, the FDA issued a Complete Response Letter for ONS-5010 / LYTENAVA, saying it could not approve the treatment in its current form for wet AMD.</li></ul>Outlook Therapeutics Inc. (OTLK) shares plunged 32% in Tuesday’s pre-market trade after the company announced a proposed public offering of its common stock and accompanying warrants.Outlook Therapeutics announced the pricing of the public offering, stating that each share of common stock and the accompanying warrant are being sold at a combined price of $0.25. The company said it expects aggregate gross proceeds of $5 million and that the offering is expected to close on Wednesday, March 25, 2026.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/OTLK">Outlook Therapeutics</a> trended in the ‘extremely bearish’ territory, with message volumes at ‘high’ levels at the time of writing.<h2 class="st-heading-2">Why Did Outlook Therapeutics Announce The Offering?</h2>Outlook Therapeutics stated that it intends to use the proceeds of the stock offering to meet its working capital requirements as well as other general corporate needs.Last week, the company announced a new $18.4 million non-convertible unsecured note financing, stating that it will use a portion of the net proceeds to pay down an existing note.Earlier this month, Outlook Therapeutics provided an update with respect to a meeting with the U.S. Food and Drug Administration (FDA) regarding the company’s Biologics License Application for its treatment of wet age-related macular degeneration (wet AMD).In December 2025, the company said that the FDA issued a Complete Response Letter for its investigational treatment, ONS-5010 / LYTENAVA (bevacizumab-vikg), stating that it cannot approve the application in its present form for the treatment of wet AMD.The company said that if the FDA approves it, bevacizumab-vikg has the potential to be the first ophthalmic formulation of bevacizumab-vikg approved by the regulator for use in ophthalmology.Bevacizumab-vikg is a lab-made antibody that targets a protein called VEGF, which helps blood vessels grow. By blocking VEGF from binding to its receptors on blood vessel cells, the drug prevents the formation of new blood vessels.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Outlook Therapeutics’ proposed offering was&nbsp;criticized&nbsp;by a user on the platform, who called out the company for not giving a roadmap on how it intends to use the money, other than meeting its working capital and general corporate needs.<stembedurl>https://stocktwits.com/HarveySpecter20/message/648356634</stembedurl>Another user highlighted the lack of data on the uptake of the investigational treatment from patients.<stembedurl>https://stocktwits.com/updownsides/message/648355300</stembedurl><a href="https://stocktwits.com/symbol/OTLK">OTLK stock</a> is down 80% year-to-date and 79% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 16% over the past 12 months, while the iShares Micro-Cap ETF (IWC) is up 38%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fidelity-backs-elon-musk-tesla-spacex-terafab-project-datacenters-in-space/cZ3mK7PRI0u">Elon Musk's Joint Tesla, SpaceX Terafab Project Makes A 'Ton Of Sense', Says Investor Fidelity: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trading digital board showing the data on global stock market crash. | Image source: Getty Images

Why Is OTLK Stock Falling Today?

Outlook Therapeutics announced the pricing of the public offering, stating that each share of common stock and the accompanying warrant are being sold at a combined price of $0.25.

<ul class="summary-bullets"><li>Apollo intends to stick to the same cap next quarter as it balances “the interests of shareholders seeking liquidity with those who choose to remain invested,” per the letter.&nbsp;</li><li>The firm expects the granted redemptions to amount to roughly $730 million of gross outflows for the first quarter.</li><li>Apollo Debt Solutions is returning less cash to clients than some of its peers that capped withdrawals, the report said.&nbsp;&nbsp;</li></ul>Apollo Global Management is reportedly curbing redemptions from one of its largest non-traded private credit funds for retail investors, sending shares down nearly 3% in extended hours of trading.&nbsp;The $25 billion business development company, Apollo Debt Solutions, capped withdrawals at 5% of outstanding shares Monday after clients sought to redeem 11.2%, according to a report from Bloomberg News that cited a shareholder letter.&nbsp;<h2 class="st-heading-2">Details</h2>With redeeming investors receiving just 45% of their capital, Apollo Debt Solutions is returning less cash to clients than some of its peers that capped withdrawals, the report said.&nbsp;&nbsp;Apollo intends to stick to the same cap next quarter as it balances “the interests of shareholders seeking liquidity with those who choose to remain invested,” per the letter. Apollo, which has been pushing for more transparency in private markets, reportedly said that Apollo Debt Solutions had returned 1% over the past three months.&nbsp;The firm expects the granted redemptions to amount to roughly $730 million of gross outflows for the first quarter, offsetting the roughly $724 million of inflows for the period, the report said.&nbsp;<h2 class="st-heading-2">Private Sector Reeling</h2>The private credit industry has been seeing a rise in redemption rates across several funds over fears about the asset class, as well as its exposure to software businesses, which are at risk of AI-related disruption.Blue Owl earlier said that it will permanently stop allowing redemptions from Blue Owl Capital Corp. II, a semi-liquid private credit fund marketed to U.S. retail investors.Blackstone’s $82 billion Blackstone Private Credit Fund (BCRED) disclosed a rise in redemption rates. BCRED’s first-quarter (Q1) redemption requests totaled 7.9% of the outstanding shares, up from 4.5% in Q4.&nbsp;<h2 class="st-heading-2">Retail reaction</h2>Retail sentiment around APO trended in ‘bearish’ territory amid ‘normal’ message volume.&nbsp;Shares in the company have fallen 24% so far in 2026.&nbsp;

 In this photo illustration, the Apollo Global Management company logo is seen displayed on a smartphone screen.

Apollo Reportedly Caps Private Credit Fund Withdrawals; Stock Dives

The $25 billion business development company, Apollo Debt Solutions, capped withdrawals at 5% of outstanding shares Monday after clients sought to redeem 11.2%, according to a report from Bloomberg News. 

<ul class="summary-bullets"><li>The company stated in its announcement that it intends to use the funds raised through this stock offering to acquire additional inventory, for working capital needs, and for general corporate purposes.</li><li>Donald Trump Jr., who is on the company’s advisory board, said that the latest capital infusion will enable Unusual Machines to build the foundation for a strong domestic drone industry.</li><li>The Florida-based company announced a public offering on Thursday to expand its U.S. drone parts inventory and for working capital and general corporate purposes.</li></ul>Unusual Machines Inc. (UMAC) on Friday announced the pricing of its public offering to raise $150 million, which includes a strategic investment from Ondas Inc. (ONDS).Unusual Machines stated that it will issue 8.8 million shares at $17 apiece, a discount of more than 9% to the stock’s closing price on Thursday.<a href="https://stocktwits.com/symbol/UMAC">Unusual Machines shares</a> were down more than 13% in Friday’s opening trade. Retail sentiment on Stocktwits about the company trended in ‘bearish’ territory, while message volume was at ‘high’ levels at the time of writing.<h2 class="st-heading-2">What Will UMAC Use These Funds For?</h2>Unusual Machines stated in its announcement that it intends to use the funds raised through this stock offering to acquire additional inventory, for working capital needs, and for general corporate purposes.“We approach capital the same way we approach operations, deliberately and with a clear plan for deployment. This raise allows us to expand inventory, support production, and continue building a reliable, U.S.-based supply chain for drone components,” said Unusual Machines CEO Allan Evans.President Donald Trump’s son, Donald Trump Jr., who is on the company’s advisory board, said that the latest capital infusion will enable Unusual Machines to build the foundation for a strong domestic drone industry.<h2 class="st-heading-2">What Does Unusual Machines Do?</h2>Unusual Machines manufactures and sells drone components and drones. It also sells small acrobatic first-person-view (FPV) drones and equipment directly to consumers.The Florida-based company announced a public offering on Thursday to expand its U.S. drone parts inventory and for working capital and general corporate purposes.<a href="https://stocktwits.com/symbol/UMAC">UMAC stock</a> is up 127% year-to-date, while ONDS stock is up 4%. The SPDR S&amp;P Kensho New Economies Composite ETF (KOMP) is up 23% over the past 12 months, while the iShares Micro-Cap ETF (IWC) is up 35%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fedex-beat-and-raise-q3-wall-street-price-target-hikes-for-fdx-stock/cZ3Xqp2RILh">FedEx's Beat And Raise Q3 Earns Street Accolades As Price Target Hikes Pour In — Analysts Flag 'Unique Combination' Of Price And Yield Growth</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is UMAC Stock Falling Today?

Unusual Machines stated that it will issue 8.8 million shares at $17 apiece, a discount of more than 9% to the stock’s closing price on Thursday.

<ul class="summary-bullets"><li>Palladyne stated that the ALRRM is capable of exceeding a distance of 350 nautical miles at an unspecified but high altitude.</li><li>This missile can cover this distance at a sustained cruise speed of beyond the required Mach 4.0.</li><li>Palladyne also stated that the ALRRM can deliver a 150-lb warhead air-breathing solid-fuel ramjet.</li></ul>Palladyne AI Corp. (PDYN) on Wednesday announced that its subsidiary has been awarded a contract by the U.S. Navy to develop new air-launched, near-hypersonic, long-range, low-cost missiles.Palladyne’s subsidiary GuideTech will develop the new Air-Launched Rapid Response Missile (ALRRM). The company said that ALRRM is expected to deliver nearly hypersonic speed and long range at a fraction of the cost of other hypersonic weapons.<a href="https://stocktwits.com/symbol/PDYN">Palladyne AI shares</a> were up more than 15% in Wednesday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘neutral’ territory. PDYN was the second most trending ticker on the platform at the time of writing.<h2 class="st-heading-2">What Is ALRRM Capable Of?</h2>Palladyne stated that the ALRRM is capable of exceeding a distance of 350 nautical miles at an unspecified but high altitude. This missile can cover this distance at a sustained cruise speed of beyond the required Mach 4.0. Palladyne also stated that the ALRRM can deliver a 150 lb warhead air-breathing solid fuel ramjet (SFRJ).“The 2025 National Security Strategy explicitly states that the U.S. must build ‘next-generation missiles with a clear and urgent need for cost-effective, high-performance strike capabilities’ for the U.S. military,” said Palladyne AI CEO Ben Wolff.Wolff added that the ALRRM can deliver on these strategic needs at a fraction of the cost.“We believe there is no other missile currently available to the U.S. military that combines the speed, range, and payload capacity of the ALRRM, at this size and price point — creating a new strike class for 5th gen fighters that is stealth-borne, near-hypersonic, and deep-theater strike,” he added.This comes amid the ongoing Iran war, with the U.S. having incurred over $11 billion in the first week of the conflict. The Trump administration could reportedly seek an additional funding of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/peter-schiff-warns-debt-risk-trump-seeks-50b-for-iran-war/cZ3EEoORIXe">$50 billion</a> to replenish the weapons stockpile of the U.S.<h2 class="st-heading-2">What Does Palladyne AI Do?</h2>Palladyne AI is a Salt Lake City, Utah-based company developing AI and autonomy solutions, advanced avionics and more for the defense and industrial markets.Earlier this month, the company reported a loss of $0.16 per share on revenue of $1.66 million, while Wall Street expected a loss of $0.14 per share on revenue of $0.81 million, according to Fiscal.ai data.<a href="https://stocktwits.com/symbol/PDYN">PDYN stock</a> is up 59% year-to-date, but down 12% over the past 12 months. The iShares Micro-Cap ETF (IWC) is up 39% over the past 12 months, while the Themes Generative Artificial Intelligence ETF (WISE) is up 1%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/will-fed-consider-rate-hikes-strategist-warns-inflation-worse-amid-iran-war/cZ37Bn2RIgW">Will The Fed Consider Rate Hikes Again? Strategist Warns Inflation Picture Could 'Get A Lot Worse' Amid Iran War</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Palladyne AI Corp. logo is seen displayed on a smartphone screen. 

Palladyne AI Subsidiary Wins US Navy Contract For Developing New Missiles — PDYN Stock Soars Pre-Market

The company said that the Air-Launched Rapid Response Missile is expected to deliver nearly hypersonic speed and long range at a fraction of the cost of other hypersonic weapons.

<ul class="summary-bullets"><li>Greenwich noted that despite the absence of a placebo arm, GLSI-100 showed an annual recurrence rate below 1%, compared with about 4% in the KATHERINE trial of Kadcyla over a similar timeframe.</li><li>The company also stated that the Phase III trial results are trending in line with those from the Phase IIb trial.</li><li>Greenwich reported a reduction of up to 80% in breast cancer recurrences, while other approved products showed a reduction of 20% to 25%, the company said.</li></ul>Greenwich LifeSciences Inc. (GLSI) shares gained more than 13% in Tuesday’s pre-market trade after the company announced that its immunotherapy trial has shown a continued reduction in the rate of recurrence of breast cancer.Greenwich LifeSciences said its 250-patient Phase III breast cancer immunotherapy trial, FLAMINGO-01, showed an annual recurrence rate below 1%.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/GLSI">Greenwich LifeSciences</a> trended in the ‘extremely bullish’ territory with message volumes at ‘extremely high’ levels. GLSI was the top trending ticker on the platform at the time of writing.<h2 class="st-heading-2">Results Show About 70-80% Reduction In Recurrence Rate, Says Greenwich</h2>Greenwich noted that despite the absence of a placebo arm, GLSI-100 showed an annual recurrence rate below 1%, compared with about 4% in the KATHERINE trial of Kadcyla over a similar timeframe.The company also stated that the results of the Phase III trial are trending in line with those from the Phase IIb results. Greenwich reported a reduction of up to 80% in breast cancer recurrences, while other approved products showed a reduction of 20% to 25%, the company said.However, Greenwich stated that these Phase III trial results are still preliminary and that the final analysis may differ.The Phase III FLAMINGO-01 trial is designed to evaluate the safety and efficacy of GLSI-100 in HER2-positive breast cancer patients with residual disease or high-risk pathological complete response who have completed neoadjuvant and adjuvant trastuzumab-based therapy.<h2 class="st-heading-2">What Does Greenwich LifeSciences Do?</h2>Greenwich LifeSciences is a clinical-stage biopharmaceutical company based out of Stafford, Texas. It is currently focused on the development of GP2, which is an immunotherapy to prevent breast cancer recurrence in patients who have previously undergone surgery.<a href="https://stocktwits.com/symbol/GLSI">GLSI stock</a> is up 34% year-to-date and 134% over the past 12 months. The iShares Russell 2000 Growth ETF (IWO) is up 22% over the past 12 months, while the iShares Micro-Cap ETF (IWC) is up 40%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-says-fed-chair-powell-should-cut-rates-right-now/cZ3PPPaRIfw">Trump Says Fed Chair Powell Should Cut Rates Right Now</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is GLSI Stock Rising Today?

Greenwich LifeSciences said its Phase III breast cancer immunotherapy trial, involving 250 patients, showed a recurrence rate of under 1% per year.

<ul class="summary-bullets"><li>The company said upon closing of the final transaction it will result in the cancellation of 1.34 million units of its publicly-traded senior notes across multiple outstanding series.</li><li>RILY said it repurchased 171,703 units of its 5.0% senior notes due 2026 (RILYG) for approximately $4.0 million in cash.</li></ul>BRC Group Holdings shares rallied more than 6% in extended hours of trading on Thursday after it announced a series of senior note transactions with an institutional investor, resulting in reduction of some of its debt.&nbsp;The company said that the closing of the final transaction will result in the cancellation of 1.34 million units of its publicly-traded senior notes across multiple outstanding series in exchange for the issuance of an aggregate of 4.2 million shares of its common stock at an average price of $7.0933 per share.<h2 class="st-heading-2">Details</h2>RILY said it repurchased 171,703 units of its 5.0% senior notes due 2026 (RILYG) for approximately $4.0 million in cash. Upon closing of the final transaction scheduled for March 13, 2026, the company's outstanding debt will be reduced by approximately $37.9 million."These senior note transactions, combined with continued appreciation in our investment portfolio, have further reduced our net debt position beyond the preliminary estimates communicated for December 31, 2025. We will continue to utilize multiple strategies to reduce debt and invest in our business,” said Bryant Riley, Chairman and Co-Chief Executive Officer of BRCGH.&nbsp;<h2 class="st-heading-2">10-K Report Expected This Month</h2>The company said that it expects to file its 2025 Annual Report on or before the extended deadline of March 31, 2026, and to announce the timing of its earnings release and earnings call next week."The Company values the enormous effort required by its team and business partners to file three Quarterly Reports on Form 10-Q between November 20, 2025 and January 14, 2026.&nbsp; Bringing these filings current while driving strong progress on our annual audit in an accelerated timeframe demonstrates the strength and resolve of our team — and positions us well for the road ahead. We look forward to discussing the Company and taking questions on the earnings call by the end of March,” Riley added.&nbsp;<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around RILY trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;Shares in the company are up 52% so far in 2026.&nbsp;

RILY said it repurchased 171,703 units of its 5.0% senior notes due 2026 (RILYG) for approximately $4.0 million in cash. 

RILY Stock Rallies After-Hours – How Much Of Its Debt Is Reduced By Latest Senior Note Transactions?

The company said upon closing of the final transaction with an institutional investor its outstanding debt will be reduced by approximately $37.9 million.

<ul class="summary-bullets"><li>The revenue fell well short of analyst estimates of $144.95 million, according to data from Fiscal.ai.&nbsp;</li><li>The company said that its gross margin for Q4 was at 13.4%, compared to gross margin of 15.3% from year-ago.&nbsp;</li><li>The company said it expects FY 2026 revenue of $500 million to $550 million. However, it fell way short of Wall Street expectations of $625.65 million.&nbsp;</li></ul>FreightCar America shares slumped 19% during extended hours of trading on Monday as it reported a decline in its fourth quarter revenue.&nbsp;The company said its revenues in Q4 came at $125.6 million,&nbsp;lower than $137.7 million in the fourth quarter of 2024, despite railcar deliveries of 1,172 units compared to 1,019 units in the prior year period.&nbsp;The revenue fell well short of analyst estimates of $144.95 million, according to data from Fiscal.ai.&nbsp;<h2 class="st-heading-2">Q4 Snapshot</h2>The company posted a fall in its profit in Q4. It reported adjusted net income of $4.9 million, or $0.16 per share, compared to $0.21 per share from the year-ago quarter. RAIL also missed profit expectations of $0.19 per share, as per Fiscal.ai.&nbsp;“In 2025, FreightCar America executed with discipline amid a challenging industry environment, delivering revenue in line with our expectations while producing exceptional profitability,” said Nick Randall, President and Chief Executive Officer of FreightCar America.The company said that its gross margin was at 13.4% with gross profit of $16.8 million, compared to gross margin of 15.3% with gross profit of $21.0 million in the fourth quarter of 2024.&nbsp;<h2 class="st-heading-2">Outlook</h2>The company said it expects FY 2026 revenue of $500 million to $550 million. However, it fell way short of Wall Street expectations of $625.65 million.&nbsp;“As we enter 2026, we remain focused on converting backlog into profitable deliveries while continuing to invest for growth,” Randall said.&nbsp;“Looking ahead to 2026, our guidance reflects ongoing industry uncertainty while reinforcing our confidence in the underlying strength and resilience of the business,” said Mike Riordan, Chief Financial Officer of FreightCar America.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around RAIL trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;Shares in the company have fallen nearly 11% so far in 2026.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Freightcar Americs said its revenues in Q4 came at $125.6 million, lower than $137.7 million in the fourth quarter of 2024. 

FreightCar America Slumps 21% As Q4 Results And FY26 Disappoints Investors

The company said its revenues in Q4 came at $125.6 million, lower than $137.7 million in the fourth quarter of 2024, despite railcar deliveries of 1,172 units compared to 1,019 units in the prior year period. 

IWC
iShares Micro-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWC News

IWCiShares Micro-Cap ETF